Athenex gains FDA approval of Klisyri in pre-cancerous skin lesion

 

• Athenex (NASDAQ:ATNX) jumps 10% premarket after FDA approved Klisyri (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp.
• Klisyri is the first FDA approved branded proprietary product for Athenex and will be launched in partnership with Almirall (OTC:LBTSF) in the U.S. during Q1 2021.
• In addition to the partnership with Almirall, Athenex has partnered with PharmaEssentia in Taiwan and with Xiangxue Pharmaceuticals in China, Hong Kong, and Macau for AK.
• Actinic keratosis is a pre-cancerous skin lesion. If left untreated, 10-15% of AK lesions will develop into skin cancers.
• https://seekingalpha.com/news/3644349-athenex-gains-10-on-fda-approval-of-klisyri-in-pre-cancerous-skin-lesion